Assembly Biosciences (NASDAQ:ASMB) Receives "Buy" Rating from HC Wainwright

Key Points

• HC Wainwright reiterated a "Buy" on Assembly Biosciences and set a target price of $50, implying roughly a 74.4% upside from current levels.
• Assembly posted a surprising quarterly beat — $2.48 EPS vs. a consensus of ($0.51) and revenue of $42.47M vs. $7.42M — but still has a negative net margin/ROE and sell-side forecasts of -6.87 EPS for the year.
• Analyst and ownership context: five Buys, one Hold and one Sell produce a consensus rating of "Moderate Buy" with a consensus target of $41.75; shares trade near $28.67 (52-week range $7.75–$39.71) and institutional investors including Farallon and RA Capital recently built sizable stakes.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $50.00 target price on the biopharmaceutical company's stock. HC Wainwright's target price suggests a potential upside of 74.40% from the stock's current price.

A number of other analysts also recently commented on the stock. Wall Street Zen upgraded shares of Assembly Biosciences from a "hold" rating to a "buy" rating in a report on Saturday, March 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $41.75.

Assembly Biosciences Stock Up 1.6%

NASDAQ:ASMB opened at $28.67 on Thursday. The business's 50-day moving average price is $27.98 and its 200 day moving average price is $29.72. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $39.71. The firm has a market cap of $454.79 million, a P/E ratio of -38.74 and a beta of 1.11.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million during the quarter, compared to the consensus estimate of $7.42 million. Sell-side analysts expect that Assembly Biosciences will post -6.87 EPS for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC purchased a new stake in Assembly Biosciences during the third quarter valued at about $31,426,000. RA Capital Management L.P. purchased a new position in shares of Assembly Biosciences in the third quarter worth approximately $26,122,000. Commodore Capital LP purchased a new position in shares of Assembly Biosciences in the third quarter worth approximately $25,600,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Assembly Biosciences during the fourth quarter valued at approximately $22,625,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Assembly Biosciences during the third quarter valued at approximately $6,425,000. Hedge funds and other institutional investors own 19.92% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.